Daman: In a landmark development for India’s sterile injectable manufacturing sector, Sovereign Pharma has successfully commissioned its first advanced isolator-based filling line, strengthening the country’s position in high-precision, contamination-controlled pharmaceutical production.
The newly inaugurated line is part of the company’s long-term modernization plan, under which three existing filling lines are being upgraded to fully contained isolator systems. With the first line now operational, Sovereign Pharma joins a select group of global manufacturers equipped with isolator technology for high-volume ampoule filling.
The state-of-the-art system creates a sealed aseptic environment using glove ports, HEPA-filtered air, positive pressure containment, and vaporized hydrogen peroxide (VHP) bio-decontamination. By drastically reducing human interaction—responsible for nearly 80% of contamination risks—the isolator ensures superior sterility assurance, greater consistency and minimized human error.
A key technological highlight of the line is the integration of online PUPSIT (Pre-Use Post-Sterilisation Integrity Testing), enabling real-time, non-destructive verification of sterilised filters prior to production. This capability places Sovereign Pharma among the very few manufacturers worldwide operating such advanced systems, further elevating product safety standards.
In a major national milestone, Sovereign Pharma becomes the first company in India to deploy an isolator-based high-volume ampoule filling line. While global guidelines mandate isolator use for aseptically filled products, the company has gone beyond regulatory compliance by introducing this technology even for terminally sterilised products, aligning its processes with the latest EU Annex 1 and USFDA expectations.
The upgraded system supports both aseptic and terminally sterilized injectable manufacturing, enhancing production flexibility, reducing turnaround times and offering customers globally benchmarked process control.
“Commissioning our first isolator-based filling line reflects our commitment to placing India at the forefront of sterile injectable manufacturing,” said Rishad Dadachanji, Director, Sovereign Pharma. “We believe in going beyond compliance and setting new benchmarks. With isolator technology enabling high-volume ampoule filling for the first time in India, we reinforce our dedication to patient safety and to delivering uncompromised quality for every client we serve.”
The isolator-based platform also enables handling of potent compounds and diverse sterile formulations. Sovereign Pharma will extend this technology to the remaining filling lines as part of its phased expansion and modernization strategy.
